Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2022 - 11 - 17 save search
TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
Published: 2022-11-17 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.56%
H: 0.52%
C: 0.52%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.2%
H: 0.0%
C: 0.0%
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: -13.59%
H: 0.0%
C: 0.0%
treatment fda approved diabetes
European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
Published: 2022-11-17 (Crawled : 21:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
enjaymo treatment disease anemia
Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
Published: 2022-11-17 (Crawled : 18:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
enjaymo treatment disease anemia
LiqTech Enters Distribution Agreement with NESR for Commercialization of Produced Water Treatment Solution for Re-Injection
Published: 2022-11-17 (Crawled : 14:20) - prnewswire.com
NESR | $9.0 -36.31% 120K
|
Industrial Services
|
| O: -2.34%
H: 3.59%
C: 1.95%
LIQT | $2.6 -3.0% 5.2K
|
Producer Manufacturing
|
| O: -0.02%
H: 14.17%
C: -3.57%
water treatment commercialization solution distribution agreement
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of VitiligoTopline proof-of-concept data in vitiligo patients expected in 1H 2023
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 4.55%
H: 0.0%
C: -6.03%
vyn201 treatment expected trial therapeutics
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
RNXT | $1.26 5.0% 4.76% 3.5K
|
|
| O: -6.71%
H: 3.98%
C: 1.3%
renovotamp treatment management symposium therapy platform
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.22%
H: 1.46%
C: 1.38%
iclusig approved trial
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
COCP | $1.562 -1.39% 3.9K
|
Health Technology
|
| O: 2.67%
H: 1.3%
C: -2.92%
cc-4234 treatment pharma antiviral influenza study cc-42344 phase 1
New Research Reveals Common Treatments for Knee Pain are Falling Short, Placing Physical, Social, and Mental Burden on Patients
Published: 2022-11-17 (Crawled : 13:20) - prnewswire.com
PCRX | $25.93 -3.28% -3.39% 360K
|
Health Technology
|
| O: -1.19%
H: 0.57%
C: 0.21%
research
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
Published: 2022-11-17 (Crawled : 13:00) - biospace.com/
ATAI | $1.875 -4.82% -5.07% 830K
|
Manufacturing
|
| O: 0.0%
H: 2.09%
C: -2.44%
treatment ketamine sciences life biomarkers depression study
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Published: 2022-11-17 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.26%
H: 1.16%
C: 0.73%
CTMX | $1.635 -2.68% -2.75% 280K
|
Health Technology
|
| O: 23.14%
H: 12.75%
C: 7.38%
treatment research collaboration therapeutics cancer
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Published: 2022-11-17 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.26%
H: 1.16%
C: 0.73%
CTMX | $1.635 -2.68% -2.75% 280K
|
Health Technology
|
| O: 23.14%
H: 12.75%
C: 7.38%
treatment research collaboration therapeutics cancer
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Published: 2022-11-17 (Crawled : 13:00) - globenewswire.com
AVTE M | $21.27 -8.4% -9.17% 300K
|
Professional, Scientific, and T...
|
| O: -1.37%
H: 4.24%
C: -1.03%
av-101 treatment research hypertension therapeutics study phase 1
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.